Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Return on Capital Employed (2016 - 2025)

Ocular Therapeutix has reported Return on Capital Employed over the past 12 years, most recently at 0.48% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.48% for Q4 2025, down 9.0% from a year ago — trailing twelve months through Dec 2025 was 0.48% (down 9.0% YoY), and the annual figure for FY2025 was 0.46%, up 8.0%.
  • Return on Capital Employed for Q4 2025 was 0.48% at Ocular Therapeutix, up from 0.66% in the prior quarter.
  • Over the last five years, Return on Capital Employed for OCUL hit a ceiling of 0.23% in Q2 2024 and a floor of 0.9% in Q2 2023.
  • Median Return on Capital Employed over the past 5 years was 0.48% (2025), compared with a mean of 0.49%.
  • Biggest five-year swings in Return on Capital Employed: surged 98bps in 2021 and later crashed -41bps in 2023.
  • Ocular Therapeutix's Return on Capital Employed stood at 0.42% in 2021, then crashed by -52bps to 0.64% in 2022, then increased by 26bps to 0.48% in 2023, then grew by 17bps to 0.4% in 2024, then decreased by -22bps to 0.48% in 2025.
  • The last three reported values for Return on Capital Employed were 0.48% (Q4 2025), 0.66% (Q3 2025), and 0.59% (Q2 2025) per Business Quant data.